Streetbeat News

Analyst Ratings

BTCUSD

DOGEUSD

ETHUSD

FLOKIUSD

PEPEUSD

Crypto analyst Ali Martinez has expressed optimism about Dogecoin (DOGE), noting that it is breaking out from a multi-year descending triangle on the DOGE weekly chart. Another analyst, Crypto Tony, also talked about DOGE, stating that a weekly closure above a particular trendline would mark the first time in 700 days. Martinez also shared insights regarding the trajectories of Bitcoin (BTC) and Ethereum (ETH), suggesting that BTC is preparing for an upward trend, but he anticipates a temporary dip to around $33,000 before the bullish breakout.

Portfolio Pulse from Mehab Qureshi

October 30, 2023 | 12:45 pm

BMY

Goldman Sachs analyst Chris Shibutani has maintained a 'Buy' rating on Bristol-Myers Squibb (NYSE:BMY), but lowered the price target from $81 to $69.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:43 pm

GTHX

Wedbush analyst David Nierengarten has reiterated an Outperform rating on G1 Therapeutics (NASDAQ:GTHX) and maintained a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:41 pm

AZUL

Goldman Sachs analyst Bruno Amorim maintains a Buy rating on Azul (NYSE:AZUL) but lowers the price target from $18.3 to $15.5.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:41 pm

CDP

Wedbush analyst Richard Anderson has reiterated an Outperform rating on COPT Defense (NYSE:CDP) and maintained a $27 price target.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:39 pm

VRDN

Viridian Therapeutics has appointed Stephen Mahoney as its new CEO and announced a $185M private placement financing. The company also unveiled its next-generation FcRn inhibitor programs for autoimmune diseases. Viridian's pipeline includes IGF-1R inhibitors for thyroid eye disease (TED) and FcRn inhibitors. The company expects to select its lead subcutaneous IGF-1R program by the end of 2023 and topline results from the first THRIVE Phase 3 clinical trial for intravenous VRDN-001 for active TED in mid-2024. The financing will extend the company's operating runway into 2026.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:38 pm

PMT

Wedbush analyst Jay McCanless has maintained a Neutral rating on PennyMac Mortgage (NYSE:PMT) and raised the price target from $13 to $14.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:37 pm

AUPH

BA

BP

CNHI

CTRA

GM

SMCI

SYM

Jim Cramer shared his views on several stocks on CNBC's 'Mad Money Lightning Round'. He said BP is 'not great, not bad' and he's sticking with Coterra Energy. He recommended Super Micro Computer and suggested waiting for CNH Industrial's earnings report. He expressed lack of confidence in Aurinia Pharmaceuticals and suggested avoiding General Motors. He recommended buying Boeing and waiting for Symbotic's earnings.

Portfolio Pulse from Lisa Levin

October 30, 2023 | 12:37 pm

SBCF

Raymond James analyst David Feaster has maintained an 'Outperform' rating on Seacoast Banking (NASDAQ:SBCF), but lowered the price target from $27 to $23.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:30 pm

SAIA

Raymond James analyst Patrick Tyler Brown maintains an Outperform rating on Saia (NASDAQ:SAIA) but lowers the price target from $450 to $420.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 12:24 pm